Agios Pharmaceuticals, Inc. (AGIO) Stake Lessened by Nationwide Fund Advisors

Nationwide Fund Advisors trimmed its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 54.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,604 shares of the biopharmaceutical company’s stock after selling 5,500 shares during the quarter. Nationwide Fund Advisors’ holdings in Agios Pharmaceuticals were worth $237,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Ameriprise Financial Inc. raised its stake in Agios Pharmaceuticals by 21.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 49,994 shares of the biopharmaceutical company’s stock worth $2,572,000 after buying an additional 8,965 shares during the period. TIAA CREF Investment Management LLC raised its stake in Agios Pharmaceuticals by 31.4% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 117,265 shares of the biopharmaceutical company’s stock worth $6,033,000 after buying an additional 28,030 shares during the period. Teachers Advisors LLC raised its stake in Agios Pharmaceuticals by 54.4% during the 2nd quarter. Teachers Advisors LLC now owns 46,733 shares of the biopharmaceutical company’s stock worth $2,404,000 after buying an additional 16,475 shares during the period. Alliancebernstein L.P. raised its stake in Agios Pharmaceuticals by 16.3% during the 2nd quarter. Alliancebernstein L.P. now owns 21,742 shares of the biopharmaceutical company’s stock worth $1,119,000 after buying an additional 3,050 shares during the period. Finally, AXA raised its stake in Agios Pharmaceuticals by 155.0% during the 2nd quarter. AXA now owns 163,987 shares of the biopharmaceutical company’s stock worth $8,437,000 after buying an additional 99,683 shares during the period. 93.16% of the stock is currently owned by institutional investors.

A number of research analysts recently weighed in on the company. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $83.00 price target (up from $75.00) on shares of Agios Pharmaceuticals in a research note on Thursday, August 10th. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $76.00 price target on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. Royal Bank Of Canada assumed coverage on Agios Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $78.00 price target on the stock. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $80.00 price target (up from $68.00) on shares of Agios Pharmaceuticals in a research note on Tuesday, August 8th. Finally, Leerink Swann raised Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $50.00 to $80.00 in a research note on Wednesday, August 2nd. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Agios Pharmaceuticals has an average rating of “Buy” and an average target price of $75.70.

In other news, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $71.10, for a total value of $284,400.00. Following the completion of the transaction, the director now directly owns 84,394 shares of the company’s stock, valued at $6,000,413.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO David P. Schenkein sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $62.20, for a total value of $373,200.00. Following the completion of the transaction, the chief executive officer now directly owns 6,000 shares of the company’s stock, valued at $373,200. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 178,908 shares of company stock valued at $12,147,719. 10.55% of the stock is currently owned by corporate insiders.

Shares of Agios Pharmaceuticals, Inc. (AGIO) opened at $61.96 on Tuesday. Agios Pharmaceuticals, Inc. has a twelve month low of $39.24 and a twelve month high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.19. The firm had revenue of $11.35 million during the quarter, compared to analyst estimates of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The company’s revenue for the quarter was up 26.4% on a year-over-year basis. During the same period in the previous year, the company posted ($1.63) EPS. equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.59 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Agios Pharmaceuticals, Inc. (AGIO) Stake Lessened by Nationwide Fund Advisors” was first posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.themarketsdaily.com/2017/11/14/agios-pharmaceuticals-inc-agio-stake-lessened-by-nationwide-fund-advisors.html.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply